PAVmed, Inc. (PAVM)

PAVmed's stock price has been influenced by a reverse stock split, business and financial updates, a leadership appointment, conference participation, ownership filings, and stock performance. The company announced a reverse stock split to address Nasdaq's minimum bid price requirement. PAVmed provided a business update and reported its fourth quarter and full-year 2025 financial results. Joseph Virgilio was appointed to lead its relaunched medical device portfolio. Lucid Diagnostics participated in the 25th Annual Needham Virtual Healthcare Conference. Recent SEC filings disclosed significant ownership stakes by individuals. While the stock experienced a decline over the past year, it showed an increase over the past six months.

Information regarding the specific demand seasonality for PAVmed Inc.'s products and services is not publicly available in the provided search results.

PAVmed Inc. is a commercial-stage medical technology company focused on acquiring, developing, and commercializing novel products that address unmet medical needs in the United States. Its major products and pipeline include CarpX, EsoCheck Esophageal Cell Collection Device, EsoGuard Esophageal DNA Test, EsoCure Esophageal Ablation Device, PortIO, Veris Cancer Care Platform, Lucid Diagnostics Inc. (subsidiary), and Veris Health Inc. (subsidiary).

PAVmed Inc. is headquartered in New York, New York, United States, with a focus on targeting unmet medical needs in the United States.

PAVmed's brand reputation has been influenced by its efforts to strengthen its financial position and advance its product pipeline. Positive events include Lucid Diagnostics processing a record volume of EsoGuard tests, securing initial concierge medicine contracts, and obtaining its first commercial insurance coverage policies. PAVmed also strengthened its capital structure and relaunched its medical device portfolio under new leadership. The company's focus on innovation in medical devices, diagnostics, and digital health contributes to its reputation.

PAVmed Inc. has a mix of institutional and individual owners. Major institutional shareholders include Captrust Financial Advisors, SBI Securities Co., Ltd., and AdvisorNet Financial, Inc. Ira Scott Greenspan is noted as the largest individual shareholder. Other significant individual insiders include Matthew Sirovich, Tasso Partners LLC, Lishan Aklog, Dennis M. McGrath, and Joshua R. Lamstein.